Loading
A phase 1/2 trial in pancreatic cancer, run by Recurv Pharma Inc, not yet recruiting.
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies is a phase 1/2, interventional study registered as NCT07504263 by Recurv Pharma Inc, with a registry enrolment figure of 66 participants, started 2026-04-23 and due to reach its primary completion in 2027-12-01. Interventions recorded: RP-001. Conditions listed: Advanced Malignancies; Oncology; Colorectal Cancer; Pancreatic Cancer; Cancer. Primary outcome: To characterize the safety and tolerability of RP-001 administered as monotherapy.. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.